Skip to main content

Table 2 Treatment administered

From: Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Treatment Age (years) Overall CTC < 5 CTC ≥ 5
Endocrine treatment 56 (36 to 82) 47 (20.0) 33 (70.2) 14 (29.8)
   Aromatase inhibitor   35 (74.5) 25 (71.4) 10 (28.6)
   Tamoxifen   8 (17.0) 6 (75.0) 2 (25.0)
   Fulvestrant   4 (8.5) 2 (50.0) 2 (50.0)
Monochemotherapy 57 (31 to 81) 45 (19.1) 23 (51.1) 22 (48.9)
   Taxane   21 (46.7) 12 (57.1) 9 (42.9)
   Othera   24 (53.3) 11 (45.8) 13 (54.2)
Combination chemotherapy 53 (23 to 78) 64 (27.2) 40 (62.5) 24 (37.5)
   Taxane + anthracycline   25 (39.1) 16 (64.0) 9 (36.0)
   Taxane + capecitabine   22 (34.4) 13 (59.1) 9 (40.9)
   Taxane + other cytotoxic agentb   7 (10.9) 5 (71.4) 2 (28.6)
   Otherc   10 (15.6) 6 (60.0) 4 (40.0)
Chemotherapy + anti-HER2 drugs 53 (28 to 81) 40 (17.0) 26 (65.0) 14 (35.0)
   Chemotherapy + trastuzumabd   30 (75.0) 17 (57) 13 (43)
   Chemotherapy + lapatinib   10 (25.0) 9 (90) 1 (10)
Chemotherapy + bevacizumab 49 (30 to 67) 39 (16.6) 19 (48.7) 20 (51.3)
   Monochemotherapy + bevacizumab   32 (82.1) 18 (56.2) 14 (43.8)
   Polychemotherapy + bevacizumab   7 (17.9) 1 (14.3) 6 (85.7)
  1. Data presented as n (%) or median (range). CTC, circulating tumor cell; HER-2, human epidermal growth factor receptor-2. aCapecitabine (n = 17), epirubicin (n = 1), vinorelbine (n = 1), gemcitabine (n = 3), carboplatin (n = 2). bTaxane + carboplatin (n = 6), taxane + gemcitabine (n = 1). c5-Fluorouracil + epirubicin + cyclophosphamid (n = 5), fluorouracil + doxorubicin + cyclophosphamid (n = 2), gemcitabine + carboplatin (n = 3). dTaxane-based chemotherapy + trastuzumab (n = 24).